The cytomegalovirus (CMV) promoter is considered to be one of the strongest promoters for driving the in vivo expression of genes encoded by DNA vaccines. However, the efficacy of DNA vaccines has so far been disappointing (particularly in humans), and this might be explained in part by histone deacetylase (HDAC)-mediated chromatin condensation. Hence, we sought to investigate whether increasing the expression of DNA vaccine antigens with the HDAC inhibitor OSU-HDAC42 would enhance the efficacy of DNA vaccines in vivo. A luciferase assay was used to determine the effects of OSU-HDAC42 on CMV promoter-driven DNA plasmids in vitro and in vivo. Three HDAC inhibitors were able to activate expression from the CMV promoter in NIH3T3 cells and MBT-2 bladder cancer cells. The expression of luciferase was significantly enhanced by co-administration of pCMV-luciferase and OSU-HDAC42 in mice. To explore whether OSU-HDAC42 could enhance the specific antitumor activity of a neu DNA vaccine driven by the CMV promoter, we evaluated therapeutic effects and immune responses in a mouse tumor natively overexpressing HER2/neu. Mice receiving OSU-HDAC42 in combination with the CMV-promoter neu DNA vaccine exhibited stronger antitumor effects than mice given the DNA vaccine only. In addition, a correlation between the antitumor effects and the specific cellular immune responses was observed in the mice receiving the DNA vaccine and OSU-HDAC42.
Introduction
DNA vaccines offer a new and powerful approach for generating antigen-specific cancer vaccines and immunotherapies. Naked plasmid DNA is cost-effective, thermostable, easy to construct, and can be easily prepared on a large scale with high purity.
1,2 Two common routes of immunization have been developed for delivering DNA vaccines for genetic immunization: intramuscular needle injection of DNA 3 and epidermal gene gun bombardment with DNA-coated gold particles. 4 Many studies have shown that gene gun-mediated immunization is far more efficient than intramuscular injection, as it elicits similar levels of antibody and cellular responses with less DNA. 5 The cytomegalovirus (CMV) promoter is considered to be one of the strongest promoters for driving the expression of genes encoded by DNA vaccines in vivo. 6 Many studies have showed the therapeutic efficacy of virus promoter-driven DNA vaccines in preclinical animal models. For example, our previous study showed that CMV promoter-driven cDNA encoding the extracellular domain of the human HER-2/neu gene had a therapeutic effect on established HER-2/neu-expressing tumors. 7 However, the therapeutic efficacy of virus promoter-driven DNA vaccines to date has mostly been disappointing in large animal models and in human clinical trials. [8] [9] [10] One possible cause for these disappointing results may be the inactivation of the virus promoter by histone deacetylase (HDAC)-mediated chromatinization of the process of transcription. 11 HDACs are enzymes that catalyze removal of acetyl groups from the e-amino group of specific lysine residues present within the histone tails. On histone deacetylation, tight packaging of the DNA because of chromatin condensation takes place, 12 which decreases the binding of transcription factors to promoters and ultimately causes gene silencing.
Many compounds that inhibit HDAC activity have been developed and characterized. On the basis of their chemical structures, major HDAC inhibitors can be classified into four categories: short-chain fatty acids, cyclic peptides, benzamide derivatives, and hydroxamic acids. 13 The availability of HDAC inhibitors accounts in large part for the identification and characterization of HDACs and the rapid advances in our understanding how HDACs repress gene transcription.
14 Recently, several studies have also showed that HDAC inhibitors can influence virus promoter-driven DNA transcription units introduced into mammalian cells or mice. For example, the HDAC inhibitors butyrate and tricostatin A both activated CMV promoter-controlled glycosyltransferase and b-galactosidase glycogenes. 15 In addition, the HDAC inhibitor trichostatin A (TSA) upregulated SV40 and CMV promoter activity in mice. 16 The HDAC inhibitor FR901228 and TSA greatly enhanced the transcriptional activity of the SV40 promoter in an enhancer-dependent manner. 17 Hence, the HDAC inhibitormediated upregulation of virus promoter-driven gene expression may be applicable in many research fields.
In this study, we hypothesized that addition of an HDAC inhibitor could enhance expression of the CMV promoterdriven neu DNA vaccine and thereby improve its therapeutic effects in an animal tumor model. To evaluate the effects of an HDAC inhibitor on the induction of antitumor immune responses by DNA vaccination, local subcutaneous injection of the HDAC inhibitor OSU-HDAC42 was evaluated in conjunction with neu DNA vaccination against a mouse tumor naturally overexpressing HER-2/neu. OSU-HDAC42 is a novel hydroxamate-tethered phenylbutyrate derivative HDAC inhibitor, and it possesses potent cytotoxicity toward prostate cancer cells and hepatocarcinoma. 18, 19 The results indicate that OSU-HDAC42 increased the expression of the neu DNA vaccine and enhanced its antitumor effects, which were associated with increases in lymphocyte infiltration and specific cytotoxic T cells.
Materials and methods
Tissue culture and chemical compounds NIH 3T3 fibroblasts (American Type Culture Collection, Manassas, VA) and MBT-2 cells (a mouse transitional cell carcinoma cell line) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 1% penicillin-streptomycin. Sodium butyrate and TSA were purchased from the Sigma Chemical Company (St Louis, MO). OSU-HDAC42 (NSC 736012) is a gift from Dr Ching-Shih Chen, and it is a novel hydroxamatetethered phenylbutyrate derivative that has received IND approval from the FDA, and it is scheduled to enter clinical trials later this year. 18, 19 NIH3T3 and MBT-2 cell transfection NIH3T3 and MBT-2 cells were transfected with 0.5 mg of pCMV-luciferase in the presence of Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Forty-eight hours after transfection (24 h after HDAC inhibitor treatment), the cells were collected for luciferase assays.
Luciferase assay Cells were collected 24 h after HDAC inhibitor treatment and the luciferase activity of the cell lysate was determined using a Promega luciferase assay kit (Promega, Madison, WI). The samples were counted for 10 s and the luciferase activity values were normalized per unit (relative light unit per second) of total protein Mice BALB/c and C3H/He mice (6-8 weeks of age) were obtained from National Cheng Kung University and approved by the National Cheng Kung University animal welfare committee.
DNA administration by gene gun with non-coated DNA The protocol and delivery device for DNA plasmid administrations by gene gun have been described earlier. 20 Briefly, for naked DNA vaccination, 1 mg of DNA plasmid dissolved in 20 ml of autoclaved double-distilled water was directly added to the loading hole near the nozzle and then delivered to the shaved abdominal region of mice at a discharge pressure of 60 psi using a lowpressure-accelerated gene gun (GDS-80) (Wealtec Technologies Co. Ltd, Taipei, Taiwan).
Bioluminescence reporter imaging BALB/c mice were administered pCMV-luciferase and received the HDAC inhibitor OSU-HDAC42 by local intraperitoneal subcutaneous injection 1 day after DNA plasmid administration. The luciferase activity on the skin of the mice was measured at 48 and 72 h after bombardment with pCMV-luciferase. The distribution of luciferase activity in treated mice was visualized using a night owl imaging unit (Berthold Technologies, Bad Wildbad, Germany) consisting of a peltier-cooled CCD slow-scan camera mounted on a light-tight specimen chamber. Images were generated by WinLight software (Berthold Technologies). For the detection of bioluminescence, mice received 100 ml D-luciferin in saline at a dose of 100 mg kg À1 (Synchem OHG, Altenburg, Germany). Mice were placed in the light-tight chamber and a grayscale photo was first taken with dimmed light. Photon emission was then integrated over a period of 5 min. Luminescence measurements are expressed as the integration of the average brightness/pixel unit expressed as photon counts emitted per second.
Detection of green fluorescent protein (GFP)-positive dendritic cells in inguinal lymph nodes from mice
This protocol was modified from one reported earlier. 20 In brief, C3H/He mice were inoculated with 1 mg pCMV-EGFP DNA plasmid (pEGFR-N1; Clontech Laboratories, Inc., Palo Alto, CA) with the HDAC inhibitor OSU-HDAC42. Inguinal lymph nodes were collected 48 h after DNA plasmid administration. The dendritic cell (DC) population was determined by staining with monoclonal anti-DC-PE antibody (eBioscience). FACSCalibur flow cytometry (BD Bioscience, Mountain View, CA) was used to determine the percentage of GFP-positive DCs in a DCgated population.
Therapeutic efficacy of the DNA vaccine C3/HeN mice were injected subcutaneously in the flank with 1 Â 10 6 MBT-2 cells in 0.5 ml PBS. At day 10, 1 mg of naked DNA vaccine in 20 ml of autoclaved double-distilled water was gene gun administered into the skin three times at weekly intervals. Control mice were injected with 1 mg pRc/CMV in 20 ml of autoclaved double-distilled water. The mice were treated with OSU-HDAC42 1 day after DNA vaccination. Tumor size was determine using a caliper at 3 day intervals and calculated using the formula for a rational ellipse: (m 1 2 Â m 2 Â 0.5236), where m 1 represents the short axis and m 2 the longer axis. Mice were killed when the mean diameter of the tumor exceeded 2000 mm 3 or the mouse was in poor condition and expected shortly to become moribund. Statistically significant differences were revealed by KaplanMeier analysis of survival.
Measurement of antineu antibody titers
The level of neu cross-reactive antibodies was determined by testing sera from the immunized mice by ELISA with human recombinant erbB2 (R&D, Minneapolis, MN)-coated wells as described elsewhere. 20 Serum immunoglobulin (Ig) G antibody response was carried out with alkaline phosphatase-conjugated rat antimouse IgG secondary antibodies (Calbiochem, Darmstadt, Germany). Color development was facilitated using 3,3 0 ,5,5 0 -tetramethylbenzidine (Sigma). After a 15-min incubation, the reaction was stopped by the addition of 100 ml of 2N H 2 SO 4 , and the OD 450 nm was determined in an ELISA micro plate reader (Dynatech MR5000 plate reader, Dynatech Lab Inc., Chantilly, VA).
In vitro cytotoxic T lymphocytes induction and activity
This protocol was modified from one reported earlier. 20 DNA-vaccinated mice were killed 1 week after the last DNA vaccination, and spleens were isolated and RBCs were removed from single-cell splenocyte suspensions using a NH 4 Cl-KCl lysis buffer. A total of 7 Â 10 6 washed splenocytes was then stimulated with 20 mg ml À1 human recombinant ErbB2 protein in RPMI 1640 medium containing 10% FBS, 20 mg ml À1 streptomycin, 20 U ml À1 penicillin, and 50 mM 2-ME (Life Technologies, Rockville, MD). On day 5, the splenocytes (effector cells) were collected and co-incubated with MBT-2-luciferase cells (target cells) at various effector: target ratios in a 96-well U-bottomed plate. After a 12-h incubation, 100 ml of supernatant was collected from each well, and released luciferase activity was assayed with luciferin using a luminometer (EG&G, Berthold, MiniLumat LB9506 luminometer, Bad Wildbad, Germany).
Immunohistochemistry
The infiltration of tumors by T cells in vaccinated mice was analyzed by immunohistochemistry using anti-CD8 antibody (53-6.7, Pharmingen, San Diego, CA) or anti-CD4 antibody (GK1.5; BD PharMingen, San Diego, CA) as described earlier. 21 The average number of infiltrating T cells was quantified by light microscopy with a Â 10 eyepiece and a Â 40 objective lens. The total number of cells in five high-power fields was counted. Three samples from three mice were analyzed.
Results
An HDAC inhibitor enhances the transcriptional activity of the CMV promoter in vitro and in vivo As the human CMV immediate-early promoter/enhancer is one of the strongest mammalian promoters, 7 we first determined whether HDAC inhibitors would enhance CMV promoter activity in vitro. MBT-2 cells and NIH3T3 cells were co-transfected with a CMV promoter-driven luciferase plasmid and three different HDAC inhibitors, TSA, OSU-HDAC42, and sodium butyrate, and luciferase activity was assessed. CMV promoter activity was strongly enhanced in MBT-2 ( Figure 1a ) and NIH3T3 cells (Figure 1b ) by each of these three different HDAC inhibitors in a dose-dependent manner. Therefore, we further investigated whether an HDAC inhibitor would increase the protein expression of a DNA plasmid under control of the CMV promoter in vivo. Luciferase was used as a reporter gene to monitor the expression of the DNA vaccine plasmid. The HDAC inhibitor OSU-HDAC42 was injected subcutaneously at the site of DNA vaccination 1 day after administration of CMV-luciferase DNA, and the luciferase activity was recorded with in vivo imaging at 48 and 72 h after DNA administration. Mice that received both OSU-HDAC42 and CMV-luciferase plasmid DNA exhibited stronger luciferase activity than mice that received plasmid DNA only (Figure 2a) . Quantitation of the luciferase expression is shown in Figure 2b . The strength of the immune response induced by a DNA vaccine usually correlates with the number of migrated DC in the inguinal lymph nodes. A greater percentage of GFPpositive DC cells were present in lymph nodes from mice injected with both pCMV-EGFP and OSU-HDAC42 (Figure 3a) . A graphic representation of the number of GFP-positive DC cells is depicted in Figure 3b . In addition, the difference between mice given 10 mg versus 100 mg OSU-HDAC42 in combination with CMV-EGFP DNA plasmid was also statistically significant (Po0.05).
Therapeutic efficacy of naked HER-2/neu DNA vaccine with or without an HDAC inhibitor on established tumors in syngeneic mice OSU-HDAC42 is a novel hydroxamate-tethered phenylbutyrate with a low nanomolar IC 50 for HDAC inhibition. In addition, it has been tested in a prostate cancer animal model and showed promising antitumor activity. 18 Therefore, we further tested the effects of OSU-HDAC42 on the therapeutic effect of HER-2/neu DNA vaccination against MBT-2 bladder tumor cells in C3H/HeN mice. The mice that received 100 mg OSU-HDAC42 in combination with a human HER-2/neu naked DNA vaccine exhibited growth delay of MBT-2 tumors (Figure 4a ) and had extended survival times relative to mice given the DNA vaccine alone (Figure 4b ). In addition, mice receiving 100 mg OSU-HDAC42 and the DNA vaccine had significantly longer lifespans than the mice receiving 10 mg OSU-HDAC42 and DNA vaccine (Po0.05).
HDAC inhibition enhanced the HER2-specific cellular immune response induced by neu DNA vaccine To examine the immunological responses induced by the combination of OSU-HDAC42 and HER-2/neu DNA vaccine, we measured total anti-p185 neu IgG in mouse serum. Anti-p185 neu IgG was detected in all mice receiving human HER-2/neu DNA vaccine with or without OSU-HDAC42. A minor increase in p185 neu antibody was observed when mice were treated with the An HDAC inhibitor enhances the antitumor activity of DNA vaccine M-D Lai et al HER-2/neu DNA vaccine and OSU-HDAC42 (10 or 100 mg), but the difference was not statistically significant in comparison with the HER-2/neu DNA vaccine treatment alone ( Figure 5 ). As our previous study indicated that cell-mediated cytotoxic immune responses had a major role in combating MBT-2 cells in the C3H animal model, 21 we further examined whether OSU-HDAC42 enhanced HER2-specific cellular immunity. Tumors form the group of mice receiving neu DNA vaccine plus 100 mg OSU-HDAC42 showed a greater infiltration of CD4 þ and CD8 þ lymphocytes when compared with tumors from the other treatment groups or the control group (Table 1) . Therefore, a correlation between the antitumor effect of HER-2/neu DNA vaccine exposed to OSU-HDAC42 and the ErbB2-specific cellular immune responses was suggested. We then examined whether the HDAC inhibitor would enhance cytotoxic immune responses. At 1 week after the last vaccination, higher cell-mediated cytotoxic immune responses to MBT-2 were observed in mice given 100 mg OSU-HDAC42 and HER-2/neu DNA vaccine when compared with mice given HER-2/neu DNA vaccine only ( Figure 6 ). Therefore, HDAC inhibition may increase the therapeutic effect of neu DNA vaccine by enhancing the expression of the encoded gene product and inducing stronger cellular immunity. An HDAC inhibitor enhances the antitumor activity of DNA vaccine M-D Lai et al
Discussion
To improve the expression of DNA vaccine-encoded antigens such as neu, usually transcription is enhanced with the CMV promoter or translation is made more efficient by improving amino acid codon preference. DNA vaccines expressed by the CMV-promoter. Combining the HDAC inhibitor and the DNA vaccine significantly improved therapeutic efficacy. As HDAC inhibitors are clinically new anticancer target therapy drugs, DNA vaccines will certainly be a promising adjuvant cancer therapy.
Several studies have showed that one type of DC in skin, Langerhans cells, migrate rapidly to draining lymph nodes after skin irritation, 22 infection 23 or painting with antigen. [24] [25] [26] In addition, DNA plasmid containing CpG motifs induced Langerhans cell migration in skin sheets, with 50% depletion occurring within 2 h. 27 It was surprising to observe that administration of OSU-HDAC42 1 day after that of CMV-enhanced green fluorescent protein (EGFP) plasmid significantly increased the number of GFP þ DCs in distal lymph nodes 48 h after plasmid administration. The elevated number of GFP þ DCs may be because of enhancement of GFP cross-presentation in keratinocytes. As OSU-HDAC42 increased antigen protein expression in transfected keratinocytes, the antigenic proteins were secreted into the surrounding environment of antigen-presenting cells and cross-presented by professional antigen-presenting cells, which in turn migrated to draining lymph nodes and induced T cells.
Administration of OSU-HDAC42 enhanced the luciferase activity because of CMV promoter-driven luciferase for only a short interval (Figure 4) , as the fold enhancement significantly decreased 48 h after OSU-HDAC42 injection. One of possible reasons for such a short-term effect is that OSU-HDAC42 exhibited apoptogenic potency and caused greater reductions in phosphor-AKT, Bcl-xl, and survivin. 19 The death of cells expressing plasmid DNA would decrease the observed luciferase activity. Co-administration of DNA encoding anti-apoptotic proteins [28] [29] [30] may avoid this cell death and further enhance the effect of OSU-HDAC42 on the induction of CMV promoter-controlled gene expression.
Our previous results indicated that combination of an HSP90 inhibitor and a DNA vaccine had additive cancertherapeutic effects. 31 However, the enhancing effect was only observed at low doses of the HSP90 inhibitor geldanamycin, as high doses inhibited the immune response. It was interesting to note that the HDAC inhibitor enhance the therapeutic effect of the DNA vaccine in a dose-dependent manner. The effects of HDAC inhibition on immune responses have been investigated before. Histone acetylation was shown to enhance memory CD8 T cells. 32, 33 Therefore, HDAC inhibition may enhance CD8 immune responses through direct immune regulation in addition to increasing antigen expression.
Although we have shown that the combination of an HDAC inhibitor and neu DNA vaccine is an effective cancer therapy, the effects of HDAC inhibition on the tumor itself and immune cells warrant detailed further study. The HDAC inhibitor TSA can downregulate MHC class I presentation of self-antigens. 34 Furthermore, HDAC11 regulates the expression of interleukin 10, which is important in immune tolerance. Inactivation of HDAC 11 in antigen-presenting cells led to impairment of T-cell responses. 35 Therefore, the selection of appropriate HDAC inhibitors specific for certain HDACs will be important for the successful development of effective DNA vaccine combination therapies.
In summary, application of the HDAC inhibitor OSU-HDAC42 during immunization significantly enhanced the vaccine's antitumor efficacy by increasing antigen expression and the antigen-specific cellular immune response to MBT-2 tumor cells. The combination of locally applied HDAC inhibitors and skin-administered naked DNA vaccines is feasible and will be of both research and clinical interest.
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